Furthermore, KDM6 inhibition using GSK-J4 decreased the expression of p53 by increasing the level of H3K27me3 within TP53 promoter region, and improved radiosensitivity in prostate cancer [202]. This evidence concerns the gene TP53 and prostate cancer.